ABVX Abivax SA

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026

Availability of the Preparatory Documents

PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinary general meeting (the “General Meeting”) will be held on May 11, 2026, at 3:00 pm (CEST), at the hotel Paris Marriott Opera Ambassador, located at 16 boulevard Haussmann in Paris (75009), France.

The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April 3, 2026 (N°2600756).

The information and preparatory documents for this General Meeting are made available to the Company’s shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company’s website:

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Patrick Malloy

SVP, Investor Relations

Abivax SA



Attachment



EN
20/04/2026

Underlying

ABVXAbivax SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 20...

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026Availability of the Preparatory Documents PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordina...

17h / 58m 1 EN
Tobias Fahrenholz
  • Tobias Fahrenholz
BUCN BUCHER INDUSTRIES AG
MERY MERCIALYS SA
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
UBS UBM DEVELOPMENT AG
ALD ALD SA
OVH OVH GROUPE
FERGR FERRARI GROUP PUBLIC LIMITED COMPANY
04/09/26 April 9, 2026 1 EN
Tobias Fahrenholz
  • Tobias Fahrenholz
BUCN BUCHER INDUSTRIES AG
MERY MERCIALYS SA
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
UBS UBM DEVELOPMENT AG
ALD ALD SA
OVH OVH GROUPE
FERGR FERRARI GROUP PUBLIC LIMITED COMPANY
04/09/26 April 9, 2026 1 FR
Martial Descoutures
  • Martial Descoutures
ABVX ABIVAX SA

Abivax : Pourquoi la maladie de Crohn est-elle un enjeu majeur pour Ab...

À ce stade, l’intérêt spéculatif autour d’Abivax semble encore largement être orienté par obefazimod dans la rectocolite ulcéreuse (RCH). Cependant, la maladie de Crohn pourrait constituer un levier de croissance supplémentaire majeur, susceptible d’élargir significativement le marché adressable et d’augmenter l’attractivité stratégique du programme. Dans cette perspective, le read-out de l’étude ENHANCE-CD, attendu au S2 26, représente l’un des catalyseurs les plus importants sur le titre. Nous...

04/09/26 April 9, 2026 1 FR
Martial Descoutures
  • Martial Descoutures
ABVX ABIVAX SA

Abivax : Why does Crohn's disease represent a major opportunity for Ab...

At this stage, speculative interest in Abivax still appears to be largely focused on obefazimod in ulcerative colitis (UC). However, Crohn's disease could represent a major additional growth driver, likely to significantly expand the addressable market and increase the strategic appeal of the programme. With this in mind, the read-out of the ENHANCE-CD study, expected in H2 2026, will be one of the most important catalysts on the project. We maintain our Outperform recommendation.

04/09/26 April 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch